AFP and hematologic disorder: Therefore, experts and scientific associations have published consensus reports and guidelines based on the results of prospective studies reporting that risk stratification, benefit/risk calculation, and individualization of AFP should be well-assessed in patients with hematologic malignancies [3,11–18].